Raleigh pharma's stock hits record high amid drug launch
Verona Pharma's market cap nears $3 billion after drug launch. Ohtuvayre sales reached $5.6 million in the third quarter. Over 5,000 Ohtuvayre prescriptions filled by October's end. A Raleigh biopharmaceutical company is nearing a $3 billion market capitalization amid the launch of its lead drug.
Verona Pharma ( (VRNA) ) has released its Q3 earnings. Here is a breakdown of the information Verona Pharma presented to its investors. Verona ...
Hosted on MSN4mon
FDA approves new COPD drug developed by firm in Raleigh. First new treatment in a decadeVerona Pharma will market ensifentrine under the brand name Ohtuvayre. Chronic obstructive pulmonary disease (COPD) makes it harder for your lungs to function, leading to shortness of breath and ...
The first-in-class dual phosphodiesterase (PDE) 3/4 inhibitor – now given the somewhat tongue-twisting brand name of Ohtuvayre – is the first inhaled product with a novel mechanism of action ...
Ritedose is the development partner and manufacturer of Ohtuvayre (ensifentrine)*, the first inhaled product with a novel mechanism of action in more than 20 years for the maintenance treatment of ...
The analyses are published in the CHEST Annual Meeting on-line supplement. Ohtuvayre (ensifentrine) is a first-in-class selective dual inhibitor of the enzymes phosphodiesterase three and ...
The firm's analysts believe the market has underestimated the potential of Verona's recently launched drug, Ohtuvayre, which is used in the treatment of Chronic Obstructive Pulmonary Disease (COPD).
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback